联邦制药(03933)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03933 联邦制药

交易中 05-05 11:31:32

9.370

-0.110

-1.16%

最高9.600	最低9.240	成交量70.57万
今开9.600	昨收9.480	日振幅3.80%
总市值184.87亿	流通市值184.87亿	总股本19.73亿
成交额659.61万	换手率0.04%	流通股本19.73亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03933","market":"HK","secType":"STK","nameCN":"联邦制药","latestPrice":9.37,"timestamp":1777951844826,"preClose":9.48,"halted":0,"volume":705700,"delay":0,"changeRate":-0.011603375527426288,"floatShares":1973000000,"shares":1973000000,"eps":1.2690178648383938,"marketStatus":"交易中","change":-0.11,"latestTime":"05-05 11:31:32","open":9.6,"high":9.6,"low":9.24,"amount":6596130,"amplitude":0.037975,"askPrice":9.38,"askSize":60000,"bidPrice":9.37,"bidSize":16000,"shortable":3,"etf":0,"ttmEps":1.3418444662095983,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1777953600000},"marketStatusCode":2,"adr":0,"listingDate":1181836800000,"exchange":"SEHK","adjPreClose":9.48,"dividendRate":0.050712,"openAndCloseTimeList":[[1777944600000,1777953600000],[1777957200000,1777968000000]],"volumeRatio":0.416427,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03933","defaultTab":"news","newsList":[{"id":"1133108422","title":"联邦制药拟回购最多10%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1133108422","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133108422?lang=zh_cn&edition=full","pubTime":"2026-04-29 12:56","pubTimestamp":1777438566,"startTime":"0","endTime":"0","summary":"联邦制药近日在公告中披露，董事会已获授一般授权，可于公司股东周年大会授权临时有效期间内，按最高相当于公司已发行股本10%的上限回购公司股份。根据公告，截至最后可行日期，公司已发行股份总数为1,973,026,508股，若相关授权获股东批准，回购规模最高可达197,302,650股。公告显示，联邦制药股价在过去一年间最高曾达每股17.98港元，最低为9.46港元。董事会认为这项回购计划符合公司及股东整体利益。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"联邦制药拟回购最多10%股份","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631681965","title":"联邦制药：2025年净利润同比减少21.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631681965","media":"南方财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631681965?lang=zh_cn&edition=full","pubTime":"2026-04-29 12:54","pubTimestamp":1777438440,"startTime":"0","endTime":"0","summary":"南财智讯4月29日电，联邦制药（03933.HK）公告，截至2025年12月31日止年度，公司总收入为人民币132.11亿元，同比下降4.0%；本公司拥有人应占年内利润为人民币20.81亿元，同比下降21.6%；每股基本盈利为人民币1.11元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604293724168897.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107825841","title":"联邦制药（03933）2025年收入132.11亿元 同比下降4%，国际化与多元研发持续推进","url":"https://stock-news.laohu8.com/highlight/detail?id=1107825841","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107825841?lang=zh_cn&edition=full","pubTime":"2026-04-29 12:53","pubTimestamp":1777438388,"startTime":"0","endTime":"0","summary":"报告期内，联邦制药实现收入132.11亿元人民币，较2024年度的137.59亿元下降4.0%。本公司拥有人应占溢利为20.86亿元，同比下降21.6%。每股基本盈利为110.65人民币分，较上一年度的146.39人民币分下降24.4%。股息方面，中期股息为16.0人民币分，末期股息为26.0人民币分，全年合计42.0人民币分，同比下降25.0%。从业务构成来看，2025年中间体产品收入为16.12亿元，原料药收入49.00亿元，制剂产品收入66.98亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"联邦制药（03933）2025年收入132.11亿元 同比下降4%，国际化与多元研发持续推进","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630372568","title":"联邦制药(03933)：TUL321胶囊获美国FDA新药临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2630372568","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630372568?lang=zh_cn&edition=full","pubTime":"2026-04-28 17:55","pubTimestamp":1777370158,"startTime":"0","endTime":"0","summary":"智通财经APP讯，联邦制药 发布公告，本公司全资附属公司珠海联邦制药股份有限公司研发的1类创新药TUL321 胶囊的新药临床试验注册申请获美国食品药品监督管理局批准，IND编号为180385。TUL321 胶囊是新一代补体B因子抑制剂。CFB为补体系统旁路途径核心限速丝氨酸蛋白酶原，病理状态下异常激活导致旁路通路失控，介导组织损伤，从而引发多种疾病。本次获批是本公司于自身免疫疾病治疗领域创新研发取得的又一重要进展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435342.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK4588","03933","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629701048","title":"联邦制药(03933)：普利尤单抗注射液获临床试验默示许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2629701048","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629701048?lang=zh_cn&edition=full","pubTime":"2026-04-22 19:17","pubTimestamp":1776856669,"startTime":"0","endTime":"0","summary":"智通财经APP讯，联邦制药 发布公告，公司全资附属公司珠海联邦生物医药有限公司研发的度普利尤单抗生物类似药特应性皮炎适应症获得中国国家药品监督管理局临床试验默示许可，受理号为CXSL2600180。度普利尤单抗是一种全人源免疫球蛋白 G4单克隆抗体，用于治疗特应性皮炎，特别是外用药控制不佳或不建议使用外用药的中重度特应性皮炎。本次获批是公司于炎症和自身免疫疾病治疗领域创新研发取得的又一重要进展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432087.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"联邦制药(03933)：普利尤单抗注射液获临床试验默示许可","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03933","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114286395","title":"中国国家药监局批准联邦制药特应性皮炎生物类似药Dupilumab临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1114286395","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114286395?lang=zh_cn&edition=full","pubTime":"2026-04-22 19:15","pubTimestamp":1776856519,"startTime":"0","endTime":"0","summary":"联邦制药国际有限公司宣布，其针对特应性皮炎的Dupilumab生物类似药临床试验申请已获得中国国家药品监督管理局批准。\n该进展标志着公司在生物制药领域的重要突破。Dupilumab作为特应性皮炎治疗的关键药物，其类似药的研发将有望为患者提供更多治疗选择。\n此次获批将推动相关临床研究工作的进一步开展。公司表示将严格按照法规要求推进后续研发进程，助力提升皮肤病治疗水平。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629170898","title":"格力电器、联邦制药，最新招聘！超多岗位，湖湘学子快来","url":"https://stock-news.laohu8.com/highlight/detail?id=2629170898","media":"政府网站","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629170898?lang=zh_cn&edition=full","pubTime":"2026-04-21 09:01","pubTimestamp":1776733260,"startTime":"0","endTime":"0","summary":"4月26日至27日，线上线下超370家次用人单位，超1.1万个次岗位，将齐聚中南大学、湘潭大学与湖湘学子共赴一场跨越山海的诚意之约！参会单位中，既有格力电器、联邦制药等上市公司及行业龙头，也有广汽集团、广东电子信息集团等大型国企，还有北京理工大学（珠海）、汕头大学、鹏城国家实验室等高水平院校及科研机构。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-04-21/doc-inhvfivk6323546.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["SGXZ49509284.SGD","LU1064131003.USD","LU1934453819.USD","HK0000181112.HKD","LU1580142542.USD","HK0000181138.USD","BK0028","BK0188","03933","LU1064130708.USD","LU2148510915.USD","LU1328615791.USD","BK1191","SGXZ81163826.USD","BK0014","BK0012","LU1979443071.USD","000651","BK0224","BK0175","BK0196","LU1781817850.SGD","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627438797","title":"国泰海通证券：维持联邦制药(03933)“增持”评级 目标价15.53港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2627438797","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627438797?lang=zh_cn&edition=full","pubTime":"2026-04-13 15:59","pubTimestamp":1776067193,"startTime":"0","endTime":"0","summary":"该行认为，联邦制药有望通过深化垂直整合产业布局，发展多元业务，丰富产品矩阵，推进制剂、原料、动保、研发互补协同发展，维持稳健的现金流动性，积极应对市场变化，逐渐走出周期底部。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20260413/20260413160030_16700.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260413/20260413160030_16700.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427696.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["03933","EWH","161027","02611"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135374306","title":"联邦制药2026年3月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1135374306","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135374306?lang=zh_cn&edition=full","pubTime":"2026-04-02 22:21","pubTimestamp":1775139666,"startTime":"0","endTime":"0","summary":"联邦制药国际控股有限公司于2026年4月2日发布2026年3月股份变动月报表。报告期为2026年3月1日至2026年3月31日。公告显示，报告期内公司已发行股本及注册股本均未发生任何变动。公司已发行股份总数为1,973,026,508股，与上月底持平，期间无新增发行、回购、注销或库藏股变动。截至报告期末，公司再次确认满足香港联交所对上市公司最低公众持股量的要求，并确认所有发行和股份变动均符合香港联交所《上市规则》及相关法律法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"9589a36a1b64e7c7d7a94166c3b09e9b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623373124","title":"【券商聚焦】中信证券：基本医保基金收支和结余整体保持稳健","url":"https://stock-news.laohu8.com/highlight/detail?id=2623373124","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623373124?lang=zh_cn&edition=full","pubTime":"2026-03-31 08:59","pubTimestamp":1774918794,"startTime":"0","endTime":"0","summary":"2026年2月医保支出同比增速回升，收支剪刀差有所收窄。该机构预计在医保基金监管力度持续加大，DRG/DIP精细化管理的推动下，2026年全年基金结余率或将延续此前节奏略有提升。医疗健康产业政策改革进入密集期，建议持续关注政策驱动下的医疗健康产业投资机会。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977773","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02367","LU1969619763.USD","LU0348766576.USD","LU1115378108.SGD","BK1617","01099","BK1588","06030","06160","IE00BPRC5H50.USD","LU0634319403.HKD","03933","02196","06821","02228","BK1100","01789","BK1593","LU1328615791.USD","LU2399975544.HKD","09926","LU0348783233.USD","01530","LU0307460666.USD","BK0028","LU1303224171.USD","LU1255011170.USD","LU0405327494.USD","09688","BK1191","BK1564","LU2488822045.USD","600030","LU1997245177.USD","LU2495084118.USD","BK1515","BK0276","LU2148510915.USD","LU1770034418.SGD","BK1583","LU2476274308.USD","BK1147","BK1161","LU1719994722.HKD","02268","HK0000165453.HKD","LU0405327148.USD","BK0012","IE00B543WZ88.USD","LU0348735423.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622845838","title":"【券商聚焦】华泰研究维持联邦制药(03933)“买入”评级 看好创新管线海外潜力及主业改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2622845838","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622845838?lang=zh_cn&edition=full","pubTime":"2026-03-27 15:18","pubTimestamp":1774595895,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华泰研究发布研报指，看好联邦制药 的创新管线UBT251的海外进展以及主业在2026年的环比改善前景，维持“买入”评级，目标价16.36港元。此外，公司GLP-1小分子药物预计于2026年第二季度提交中美临床试验申请，同样具备对外授权潜力。另一方面，报告认为公司主营业务有望在2026年环比修复。财务方面，公司2025年实现收入132.11亿元人民币，归母净利润20.86亿元人民币。报告预计公司2026-2028年每股盈利分别为0.45元、0.55元和0.68元人民币。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/NzE1NDA5NTM3ODk1OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/NzE1NDA5NTM3ODk1OQ==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977512","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622181617","title":"中金：维持联邦制药(03933)跑赢行业评级 目标价16.00港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622181617","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622181617?lang=zh_cn&edition=full","pubTime":"2026-03-27 10:16","pubTimestamp":1774577819,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，由于原料药及中间体价格压力，下调联邦制药26/27净利润63.5%/41.5%至9.57亿元/17.56亿元。此外，UBT37034临床前数据显示与GLP-1联用可显著降低体重，并已于2026年3月完成中国I期首例受试者入组;口服小分子UBT48128公司预计于2026年提交中美临床申请。国际化方面，人用制剂实现出口收入5.54亿元 ，胰岛素产品首年规模化出海即中标巴西卫生部标单，出口量创中国同类产品纪录。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112455116","title":"联邦制药将于2026年派发末期股息每股0.26元","url":"https://stock-news.laohu8.com/highlight/detail?id=1112455116","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112455116?lang=zh_cn&edition=full","pubTime":"2026-03-26 16:36","pubTimestamp":1774514182,"startTime":"0","endTime":"0","summary":"联邦制药(03933)\n关键信息：  \n• 公告日期：2026年3月24日  \n• 截至2025年12月31日止年度将派发末期股息  \n• 每股股息：人民币0.26元  \n• 股息派发日：有待公布\n股息分派要点：  \n• 除净日：2026年7月7日  \n• 最后过户时间：2026年7月8日16:30  \n• 暂停办理股份过户登记日期：2026年7月9日至2026年7月10日  \n• 记录日期：2026年7月10日\n（以上信息均根据公司公告内容整理）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622183544","title":"瑞银：降联邦制药(03933)目标价至17.6港元 去年业绩符预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2622183544","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622183544?lang=zh_cn&edition=full","pubTime":"2026-03-26 13:57","pubTimestamp":1774504629,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞银发布研报称，考虑到联邦制药UBT251早期里程碑付款轻微下调，下调联邦制药2026至2028年每股盈测至0.66元、0.82元及1.05元，目标价由18.9港元下调至17.6港元，维持“买入”评级。联邦制药2025年全年收入同比跌4%至132亿元人民币(下同)，大致符合该行及市场预期；净利润同比跌21.6%至21亿元，略高于初步业绩。单计下半年，收入同比跌13.5%至57亿元，净利润同比跌84%至1.92亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419367.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118282523","title":"三重激动剂UBT251在中国2型糖尿病患者二期试验中，24周后糖化血红蛋白平均降幅高达2.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=1118282523","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118282523?lang=zh_cn&edition=full","pubTime":"2026-03-25 14:01","pubTimestamp":1774418480,"startTime":"0","endTime":"0","summary":"联邦制药研发的三重激动剂UBT251，在中国2型糖尿病患者中开展的二期临床试验取得积极结果。数据显示，经过24周的治疗后，患者糖化血红蛋白水平实现显著下降，平均降幅最高达到2.16%。该结果凸显了UBT251在血糖控制方面的潜在疗效，为后续临床研究提供了有力支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622104945","title":"联邦制药附属创新药UBT251 II期临床研究获成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2622104945","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622104945?lang=zh_cn&edition=full","pubTime":"2026-03-25 12:10","pubTimestamp":1774411800,"startTime":"0","endTime":"0","summary":"3月25日，联邦制药（03933）发布公告，宣布其全资附属公司联邦生物科技（珠海横琴）有限公司自主研发的1类创新药UBT251注射液已完成在中国2型糖尿病患者中的II期临床研究。此次研究共纳入211名患者，基线平均糖化血红蛋白（HbA1c）为8.12%，基线体重为80.1kg，基线BMI为29.1kg/m2。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603253683821422.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","159992","BK1191","06978","03933","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102933321","title":"联邦制药UBT251注射液II期临床试验治疗2型糖尿病达预期效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1102933321","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102933321?lang=zh_cn&edition=full","pubTime":"2026-03-25 12:03","pubTimestamp":1774411389,"startTime":"0","endTime":"0","summary":"联邦制药宣布，其研发的UBT251注射液针对2型糖尿病患者的II期临床试验已顺利完成，并达到预设的主要研究终点。试验数据显示，该药物在有效性和安全性方面均表现出良好结果，为后续临床开发奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621909659","title":"联邦制药(03933)公布2025年业绩 公司拥有人应占溢利约20.86亿元 同比减少21.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621909659","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621909659?lang=zh_cn&edition=full","pubTime":"2026-03-24 23:05","pubTimestamp":1774364711,"startTime":"0","endTime":"0","summary":"智通财经APP讯，联邦制药 公布2025年业绩，收入约132.11亿元，同比减少4%;公司拥有人应占本年度溢利约20.86亿元，同比减少21.6%;每股基本盈利110.65分，拟派末期股息每股26分。中间体产品及原料药分部溢利大幅下滑，主要受产品市场价格下跌影响。制剂产品分部溢利大幅上升主要受惠于来自诺和诺德的许可费收入。年内，集团已顺利收取此次交易预付款。随着 UBT251 项目的推进，集团将陆续实现里程碑收益，进一步兑现产品价值。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418383.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"联邦制药(03933)公布2025年业绩 公司拥有人应占溢利约20.86亿元 同比减少21.6%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194548422","title":"联邦制药2025年收入132.106亿元 研发投入加码强化创新布局","url":"https://stock-news.laohu8.com/highlight/detail?id=1194548422","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194548422?lang=zh_cn&edition=full","pubTime":"2026-03-24 23:04","pubTimestamp":1774364689,"startTime":"0","endTime":"0","summary":"联邦制药于2015年度录得收入132.106亿元，同比下降4.0%；毛利为55.141亿元，较上年减少9.3%。未计利息、税项、折旧及摊销前溢利为32.472亿元，同比下降17.6%，除税前溢利25.27953亿元，同比下跌23.1%。本公司拥有人应占溢利为20.85902亿元，同比减少21.6%，每股基本盈利110.65分，同比下滑24.4%。董事会建议派发年度合计股息42分。财务管理方面，集团通过外部借贷与短期融资管控优化资金结构，年末现金及现金等价物余额106.0639亿元，流动负债维持在合理水平。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621095723","title":"【券商聚焦】交银国际：CXO行情持续回暖 料板块估值倍数合理","url":"https://stock-news.laohu8.com/highlight/detail?id=2621095723","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621095723?lang=zh_cn&edition=full","pubTime":"2026-03-23 10:25","pubTimestamp":1774232735,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，多重利好因素共振下，2025年以来CXO行情持续回暖。该机构建议重点关注标的细分赛道成长力、核心能力布局、盈利和订单增长能见度、地缘风险敞口及估值上升空间。基于此，该机构首推药明合联，首次覆盖并重点推荐凯莱英和康龙化成。","market":"us","thumbnail":"https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977006","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2476274720.SGD","BK1197","LU1303224171.USD","BK1500","LU0634319403.HKD","LU0417516738.SGD","BK1593","BK1585","LU0348766576.USD","LU0417516902.SGD","BK1588","LU0348784397.USD","02228","01530","BK1574","BK1617","LU0307460666.USD","LU2488822045.USD","LU2399975544.HKD","02196","09926","LU2476274308.USD","06821","02367","LU1770034418.SGD","BK1141","BK1207","LU0348735423.USD","LU1719994722.HKD","03933","LU0348767384.USD","BK1583","01099","LU0540923850.HKD","LU2778985437.USD","IE00BPRC5H50.USD","06160","BK1161","LU0417516571.SGD","CXO","LU1794554557.SGD","02268","09688","03329","LU2328871848.SGD","LU0348827113.USD","BK1191","IE00B543WZ88.USD","LU1115378108.SGD","01789"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tul.com.cn","stockEarnings":[{"period":"1week","weight":-0.0063},{"period":"1month","weight":-0.1006},{"period":"3month","weight":-0.1973},{"period":"6month","weight":-0.2379},{"period":"1year","weight":-0.2914},{"period":"ytd","weight":-0.1821}],"compareEarnings":[{"period":"1week","weight":0.0066},{"period":"1month","weight":0.039},{"period":"3month","weight":-0.0275},{"period":"6month","weight":0.0062},{"period":"1year","weight":0.1596},{"period":"ytd","weight":0.0182}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"联邦制药国际控股有限公司是一家投资控股公司，主要从事销售中间体产品、原料药及制剂产品业务。该公司通过三个业务部门运营业务。中间体部从事销售中间体产品业务。原料药部从事销售原料药业务。制剂产品部从事销售抗生素制剂产品、非抗生素制剂产品及空心胶囊业务。该公司通过其子公司还从事制造及销售有机化肥业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.368421,"avgChangeRate":-0.033088},{"month":2,"riseRate":0.736842,"avgChangeRate":0.076003},{"month":3,"riseRate":0.631579,"avgChangeRate":0.024575},{"month":4,"riseRate":0.578947,"avgChangeRate":0.07559},{"month":5,"riseRate":0.684211,"avgChangeRate":0.039105},{"month":6,"riseRate":0.277778,"avgChangeRate":-0.012388},{"month":7,"riseRate":0.526316,"avgChangeRate":0.011895},{"month":8,"riseRate":0.473684,"avgChangeRate":0.025474},{"month":9,"riseRate":0.421053,"avgChangeRate":-0.006971},{"month":10,"riseRate":0.631579,"avgChangeRate":-0.000903},{"month":11,"riseRate":0.473684,"avgChangeRate":-0.023163},{"month":12,"riseRate":0.421053,"avgChangeRate":0.011153}],"exchange":"SEHK","name":"联邦制药","nameEN":"UNITED LAB"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"联邦制药(03933)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供联邦制药(03933)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"联邦制药,03933,联邦制药股票,联邦制药股票老虎,联邦制药股票老虎国际,联邦制药行情,联邦制药股票行情,联邦制药股价,联邦制药股市,联邦制药股票价格,联邦制药股票交易,联邦制药股票购买,联邦制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"联邦制药(03933)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供联邦制药(03933)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}